Uterine XXXX : prognostic factors and treatment evaluation.

@entity1 @entity242 @entity5 @entity6019 @entity1822 @entity6962
BACKGROUND: Uterine @entity242 constitutes a highly malignant group of uterine @entity5 . It accounts for 2-6% of uterine @entity5 and its incidence is 1.7 in 100,000 @entity1 . The three most common variants of uterine @entity242 are @entity6019 , @entity1822 and @entity6962 . Based on relatively small case series, the literature provides little information on the risk factors, the natural course of the disease and the preferred treatment. OBJECTIVES: To evaluate uterine @entity242 @entity1 treated in a tertiary referral center in Israel over a 20 year period (1980-2005). METHODS: We conducted a retrospective review of the charts of 40 uterine @entity242 @entity1 , including their @entity5 characteristics, stage at diagnosis, treatment modalities, follow-up and survival. RESULTS: The @entity1 ' mean age was 53 years (range 32-76); 30% of the @entity1 had @entity6962 , 55% had @entity1822 and 15% had ESS. Half of the @entity1 presented with stage I disease, 23% stage II, 10% stage III and 15% stage IV. Thirty-nine @entity1 were treated with surgery. Adjuvant radiotherapy was administered to 39% of the @entity1 , adjuvant chemotherapy to 21% and combined radiotherapy and chemotherapy to 9%. The mean follow-up period was 44 months, at which time disease had recurred in 44% of the @entity1 . The disease stage was correlated with the 5-year survival rate, which was 73.1% for stages I-II and 22.2% for stages III- IV. CONCLUSIONS: In accordance with other larger studies our data show that the only prognostic factor that was significantly correlated with prognosis was the stage of the disease at diagnosis. Despite advances in diagnosis and treatment, survival has not improved over the last 25 years.
